In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …

Atrial fibrillation (AF) is a major cause of stroke and thromboembolism, resulting in
substantial morbidity and mortality. For the majority of patients with AF, aspirin has a limited …

Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of
subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial …

Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of
death for both males and females in developed countries. Aspirin is the most widely used …

Background The benefit of aspirin to prevent cardiovascular events in subjects without
clinical cardiovascular disease relative to the increased risk of bleeding is uncertain …

Background—Low-dose aspirin is an important therapeutic option in the secondary
prevention of myocardial infarction (MI) and ischemic stroke, especially in light of its unique …

This review considers the role of low-dose aspirin for the prevention of atherothrombosis,
discussing the molecular mechanism of action of aspirin as well as clinical and …

Although conceived at the end of the 19th century as a synthetic analgesic agent with
improved gastric tolerability vs. naturally occurring salicylates, acetylsalicylic acid (marketed …

Aims The role of aspirin in the primary prevention setting is continuously evolving. Recent
randomized trials have challenged the role of aspirin in the primary prevention setting …

Aspirin protects against atherothrombosis while increasing the risk of major bleeding.
Although it is widely used to prevent cardiovascular disease (CVD), its benefit does not …